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Abstract
We screened a library of botanical compounds purified from plants of Vietnam for modula-
tors of the activity of a two-pore domain K+ channel, TREK-1, and we identified a hydroxy-
coumarin-related compound, ostruthin, as an activator of this channel. Ostruthin increased
whole-cell TREK-1 channel currents in 293T cells at a low concentration (EC50 = 5.3 μM),
and also activity of the TREK-2 channel (EC50 = 3.7 mM). In contrast, ostruthin inhibited
other K+ channels, e.g. human ether-à-go-go-related gene (HERG1), inward-rectifier
(Kir2.1), voltage-gated (Kv1.4), and two-pore domain (TASK-1) at higher concentrations,
without affecting voltage-gated potassium channel (KCNQ1 and 3). We tested the effect of
this compound on mouse anxiety- and depression-like behaviors and found anxiolytic activ-
ity in the open-field, elevated plus maze, and light/dark box tests. Of note, ostruthin also
showed antidepressive effects in the forced swim and tail suspension tests, although previ-
ous studies reported that inhibition of TREK-1 channels resulted in an antidepressive effect.
The anxiolytic and antidepressive effect was diminished by co-administration of a TREK-1
blocker, amlodipine, indicating the involvement of TREK-1 channels. Administration of
ostruthin suppressed the stress-induced increase in anti-c-Fos immunoreactivity in the lat-
eral septum, without affecting immunoreactivity in other mood disorder-related nuclei, e.g.
the amygdala, paraventricular nuclei, and dorsal raphe nucleus. Ostruthin may exert its
anxiolytic and antidepressive effects through a different mechanism from current drugs.
Introduction
Anxiety and depression are common mental disorders, for which most patients are treated
with medication. However, anxiolytic medicines can lead to tolerance and dependence [1]. In
addition, approximately one-third of patients with depression are resistant to current antide-
pressants, such as serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhib-
itors [2]. Therefore, new medicines, for which the mechanism of action is different from
current ones, are desired for the treatment of these mental disorders.
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Potassium (K+) channels play a pivotal role in the regulation of excitability of the central
neurons. Among the broad range of K+ channel families, the most recently identified family is
the two-pore domain K+ (K2P) channels responsible for background K+ currents, which are
also known as leak K+ currents [3]. Mammalian K2P channels now include 15 members, one
of which is the TWIK-related K+ channel, TREK-1. These channels are highly expressed in the
central nervous system [4, 5] and are suggested to be involved in mental diseases, i.e. anxiety
and depression [6, 7]. For instance, TREK-1-deficient mice showed a depression-resistance
phenotype through activation of the dorsal raphe nucleus (DRN), which provides serotonergic
innervation [6]. Riluzole, which activates TREK-1 channels in addition to Na+ channels and
glutamate receptor blockade, showed anxiolytic effects [8]. Therefore, TREK-1 channel activa-
tors and blockers are possible candidate for anxiolytic and antidepressive drugs, respectively.
TREK-1 channels can be activated or inhibited by several chemical compounds. For example,
TREK-1 channels are activated by arachidonic acid, volatile anesthetic (chloroform, diethyl
ether, halothane, and isoflurane), and riluzole [9], and inhibited by fluoxetine [10] and bupiva-
caine [11]. However, TREK-1 modulating activities are only side effects of these compounds,
and they have major activities elsewhere, e.g. serotonin uptake inhibition and blockade of Na+
channels. Currently, there seems to be no TREK-1-specific compound that can regulate the
pharmacological activity of this channel.
Plants cells express K+ channels, the structures of which are similar to those of mammalian
K+ channels [12, 13]. In addition, tropical and semitropical plants also produce compounds
that modify K+ channel function [14, 15]; therefore, botanical compounds are a promising
resource for K+ channel modifiers. In this study, we screened a library of botanical com-
pounds, which were isolated from plants in Vietnam, for a modulator of TREK-1 channel
activity using whole-cell patch clamp recordings. We identified a TREK-1 activator, ostruthin,
which had anxiolytic and antidepressive activities in mice. Ostruthin suppressed stress-
induced increases in c-Fos expression in the lateral septum without affecting that in the amyg-
dala or DRN, suggesting a possible difference in the mechanism of action from current drugs.
Materials and methods
Purification of ostruthin
The roots of Paramignya trimera were collected in Khanh Hoa province Vietnam in 2014 and
dried. The material (200 g) was powdered and extracted with methanol at room temperature,
and the methanol was evaporated under reduced pressure at 45˚C. The crude extract was dis-
solved in CH2Cl2 at room temperature with sonication. After solvent evaporation at 40˚C, the
sample was separated to 7 fractions by silica gel column chromatography, and the fourth frac-
tion was again chromatographed on a silica gel column with an increasing concentration of
ethyl acetate mixed with n-hexane (5.0–6.7%). Ostruthin was purified to homogeneity
(> 99.1%) according to the chromatogram of A330 nm.
Patch-clamp recordings
For recordings of K+ channel currents, we prepared stable cell lines for TREK-1, TWIK-related
acid-sensitive K+ channel (TASK-1), strongly inwardly rectifying K+ channel (Kir2.1), and
human ether-a-go-go-related gene (HERG-1) channels and transiently expressed other chan-
nels in 293T cells using a calcium-phosphate transfection method. For the establishment of the
stable lines, we used lentiviral vectors, and the preparation methods for the lentiviral vectors
were described in our previous report [16]. TR-1 cells, which stably expressed TREK-1 channel
and were grown on a small cover glass (3 × 18 mm), were placed in a recording chamber with
an internal volume of 200 μl. Whole-cell currents were recorded in Tyrode solution using an
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Axopatch 200B amplifier (Axon Instruments, Foster City, CA) at 25˚C. Tyrode solution con-
tained (in mM): NaCl 140, KCl 5.4, NaH2PO4 0.33, CaCl2 2, MgCl2 1, HEPES 5, and glucose
5.5 (pH 7.4 adjusted with NaOH). Patch pipettes pulled from borosilicate glass (Narishige,
Tokyo, Japan) were filled with an internal solution containing (in mM): K-aspartate 66, KCl
71.5, KH2PO4 1, EGTA 5, HEPES 5, and MgATP 3 (pH 7.4 adjusted with KOH). Recordings
were digitized at 10 kHz, and low-pass filtered at 2 kHz. Step pulses were applied from a hold-
ing potential of -70 mV. Test compounds were initially dissolved in dimethyl sulfoxide
(DMSO) at a higher concentration (100 mM) and then diluted with Tyrode solution by mixing
vigorously for several minutes. After the run-up ended, Tyrode solution containing a test com-
pound (200 μl) was added to the chamber using a pipette over 10 seconds. Perfusion (100 μl/
min) was continued to maintain the water level throughout recordings. pH and osmotic pres-
sure of solutions were measured with a pH meter (Horiba, Kyoto, Japan) and a freezing point
osmometer (Knauer, Berlin, Germany), respectively.
Behavioral tests
Male ICR mice (n = 317 in total) aged 5 weeks and weighing 32 ± 2 g were purchased from Shi-
mizu Laboratory Supplies (Kyoto, Japan). For the social defeat stress test, we used 28 C57BL/6J
mice (5 weeks old, Shimizu Laboratory Supplies) and 30 ICR mice (7–8 weeks old, Charles
River Labs Japan, Yokohama, Kanagawa, Japan). Mice were maintained for at least 1 week
prior to experiments. Animals were kept in groups in plastic cages. They had free access to
food and water, and were kept in a 12-h light/dark cycle (08:00–20:00). Experiments were car-
ried out between 10:00 and 18:00 in a quiet and air-conditioned experimental room, in which
mice were habituated for at least 30 min before each experiment. Animal experiments were
performed in accordance with the guidelines of the Physiological Society of Japan and were
approved by the Committees on Animal Experiments at Kansai Medical University and the
Kurashiki University of Science and the Arts. Ostruthin was initially dissolved in DMSO at
higher concentration (100 mM) and then diluted in phosphate-buffered saline (PBS). The
diluted solution was mixed vigorously for more than 10 min before the experiments, and an
equal volume of DMSO was added to PBS as a control. PBS and ostruthin were administered
intraperitoneally 30 min before mice behavioral tests (0.01 ml/g body weight). Each animal
was used only once, except for the wheel running test, which was carried out immediately after
elevated plus maze.
Open-field test
The open-field test was performed in accordance with a previous report [17] with minor modi-
fications. The open-field consisted of a square (90 × 90 cm), in which the floor was divided
into 16 equal squares. After a mouse was placed in a corner of the open field facing the wall,
the number of the entries into the central squares, and whole line crossings were counted for 5
min. After removal of animal, the apparatus was cleaned and wiped.
Elevated plus maze
The elevated plus maze apparatus consisted of four arms set in a cross pattern from a neutral
central square (6 × 6 cm). Two opposite arms were delimited by vertical walls (closed arms,
30 × 15 × 6 cm), whereas the other two arms had unprotected edges (open arms, 30 × 6 cm).
The maze was elevated 40 cm above the floor. At the beginning of each 5 min test session, a
mouse was placed in the central neutral area, facing one of the open arms. The total number of
the entries to open arms and time spent in the open arms were measured. After removal of the
animal, the apparatus was cleaned and wiped.
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Light/Dark box
The light/dark box consisted of two compartments with a total exterior size of 46 × 27 × 30
cm. One-third of the box was used as a dark compartment, which was covered with a black
wall and lid, and the rest of the area was used as a light compartment. These compartments
were connected via a small opening (7 × 7 cm), enabling transition between the two compart-
ments. We placed a mouse in the center of the light area and measured the time spent in the
light area and the number of transitions between the light and dark compartments for 5
minutes.
Forced swim test
The forced swim test was performed in accordance with a method reported previously [18].
Briefly, mouse was placed into a 2 L glass beaker containing 12 cm of water (25–27˚C). Mouse
was allowed to swim for 6 min and the activity was measured. The duration of immobility is
defined as the absence of activity, such as escape-oriented behaviors. The last 4 min of data
were used for analysis. A mock experiment was performed 1 day before the real test.
Tail suspension test
The tail suspension test was performed in accordance with a method reported previously [19].
The mouse was hung on a hook using adhesive tape placed 2 cm from the extremity of its tail
50 cm above the table. The amount of time spent immobile was recorded for 5 min.
Social defeat stress test
Social defeat stress test was carried out according to a previous report [20]. A test mouse
(C57BL/6J) was exposed to an aggressor mouse (ICR) for 10 min, and then these mice were
maintained in the same cage but separated by a plastic plate with small holes. The next day,
C57BL/6J mouse was exposed to another unfamiliar aggressor mouse, and this was repeated 9
times in total. On the 10th day, the test mouse was placed in an open-field arena, which has a
wire-mesh enclosure for social interaction testing. The target zone (14 cm × 24 cm) encom-
passes a rectangular area around the wire-mesh enclosure. Time spent in the target zone was
measured firstly with the empty mesh enclosure for 150 sec. After an interval of 30 sec, the sec-
ond test was done with an unfamiliar ICR mouse present in the enclosure. The time spent in
the target zone with empty enclosure was subtracted from that with the aggressor mouse.
Wheel running test
Immediately after the elevated plus maze test, the same mouse was subjected to the voluntary
wheel running test. The number of rotations was measured for 5 min using an activity moni-
toring running wheel (Muromachi Kikai, Tokyo, Japan).
Anti-c-Fos immunostaining
The mouse was put into an anesthetizing jar and isoflurane (>0.2 ml) was added to the jar.
After confirming that mouse was deeply anesthetized, its brain was fixed by transcardiac perfu-
sion with 4% paraformaldehyde in PBS. The brains were sliced coronally (100 μm in thickness)
using a microslicer (PRO7, Dosaka, Kyoto, Japan). The free-floating slices were reacted with
an anti-c-Fos antibody (1: 200, goat, Santa Cruz, Dallas, TX) dissolved in PBS containing
0.3% BSA and 0.3% Triton-X-100, at 4˚C for 48 h. The immunoreaction was visualized using
a secondary antibody (rabbit anti-goat IgG, Vectastain Elite ABC-HRP Kit, Vector Labs,
Antidepressive and anxiolytic effects of ostruthin, a TREK-1 channel activator
PLOS ONE | https://doi.org/10.1371/journal.pone.0201092 August 15, 2018 4 / 19
Burlingame, CA) and 3,3’-Diaminobenzidine (DAB, Tokyo Chemical Industry, Tokyo, Japan)
at room temperature in accordance with the manufacturer’s instructions.
For statistical analysis, the number of c-Fos-immunoreactive cells was quantified using the
Image-J software. Briefly, fields (0.16 mm2) of c-Fos immunoreactivity were acquired by a
microscope IX70 (Olympus) using a CCD camera. DAB-positive nuclei, of which diameters
were longer than 7 μm, were considered as anti-c-Fos-immunoreactive neurons. The immu-
noreactive cell numbers were normalized to cells/mm2.
Statistical analysis
Data are given as the mean ± SEM. The normality of data distribution was confirmed with the
Shapiro-Wilk test. Statistical significance between two groups was determined using Student’s
t-test. Those obtained from three or more groups were analyzed statistically by one-way analy-
sis of variance (ANOVA) followed by Bonferroni test. A p value of<0.05 was considered sig-
nificant. The number of asterisks indicates the p values: , p<0.05; , p< 0.01; , p<0.005.
Results
Activation of TREK-1 channels by ostruthin
We previously prepared a lentiviral vector that expressed the TREK-1 channel [16] and using
this vector we established a cell line, TR-1, which stably expressed the channel [21]. First, we
confirmed the expression of the channel current in this cell line with whole cell patch-clamp
recordings. Immediately after whole-cell access, small outward currents were recorded in
response to depolarizing step pulses (Fig 1A, 0 min). As reported previously [21], the channel
current exhibited a gradual and spontaneous increase, which is called run-up, and reached a
maximum level 3 min after establishing the whole-cell access. After the end of run-up (5 min),
the current amplitude was the same as at 3 min (Fig 1A and 1C). Therefore, in the following
screening assays, test compounds were applied 5 min after the establishment of whole-cell
access.
We tested dozens of botanical compounds and found that a hydroxyl coumarin-derivative,
ostruthin, had TREK-1 channel activating activity; the application of compounds increased the
current even after the end of the run-up in a dose-dependent manner (Fig 1A, 1C and 1E).
The increased current after the application of ostruthin was inhibited nearly completely by a
TREK-1 selective blocker, bupivacaine (3 mM), suggesting that the increased current was
attributable to the channel. The EC50 of activation was 5.3 μM.
TREK-1 channels are known to be activated by low pH and mechanical stretch [22]. There-
fore, it is possible that the addition of ostruthin containing solution activated the channel
through the changes in pH or osmotic pressure. To test these possibilities, we measured the
pH of Tyrode solution before and after addition of 100 μM ostruthin, and observed no signifi-
cant change (from 7.31 ± 0.17 to 7.33 ± 0.22, p = 0.645, paired t-test, n = 6). The addition of
ostruthin, which was initially dissolved in DMSO at 100 mM, to a final concentration of
100 μM significantly increased the osmotic pressure (from 284.0 ± 11.8 to 297.0 ± 16.8 mOsm/
L, n = 6, p< 0.01, paired t-test). This increase in the osmotic pressure was simply due to the
DMSO. Indeed, addition of an equivalent amount of DMSO resulted in the similar increase
(from 280.5 ± 10.5 to 297.2 ± 17.5 mOsm/L, n = 6, p< 0.01 paired t-test). To exclude the possi-
bility that DMSO and accompanying increase in the osmotic pressure had the activating effect
on TREK-1 channel, we applied DMSO up to 2%. We found no effect on the TREK-1 current
(Fig 1B and 1D), excluding the possibility that the activation was caused by the mechanical
stretch. Ostruthin increased the current at all voltages tested (Fig 1C), suggesting voltage-inde-
pendency of the activation. We next tested the effect of ostruthin on TREK-2 channel, which
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was transiently expressed in 293T cells. Ostruthin activated the TREK-2 channel current at
higher concentrations (EC50 3.7 mM) compared with TREK-1 (Fig 2). TREK-2 channel was
reported to be insensitive to bupivacaine at 100 μM [23], but addition of a high concentration
of bupivacaine (3 mM) almost blocked the current. This result suggests that TREK-2 was
slightly sensitive to bupivacaine and that the increased current was attributable to the TREK-2
channel current, not to the deterioration of the patch-clamp recording condition.
Ostruthin inhibited other K+ channels
To examine the effect of ostruthin on other K+ channel families, we made whole-cell record-
ings from cells expressing TASK-1 and -3, Kir2.1, Kv1.4, HERG-1 and -3, KCNQ-1 and -3,
and applied the compound to cells expressing these channels. Ostruthin inhibited these chan-
nels at higher concentrations in a concentration-dependent manner (Fig 3A–3D). The IC50
values of these channels were: 41 μM (TASK-1, Fig 3A), 227 μM (TASK-3), 198 μM (Kir 2.1,
Fig 3B), 269 μM (Kv1.4, Fig 3C), and 216 μM (HERG-1, Fig 3D). Ostruthin had no effect on
Fig 1. Activation of TREK-1 currents by ostruthin. (A) Run-up and ostruthin-induced increases in whole-cell TREK-1 currents. Step-pulses,
which are indicated in the protocol, evoked outward rectified currents immediately after whole-cell access was made (0 min). Because of the
run-up, the whole-cell TREK currents increased gradually and reached a plateau at 3 min, without further increase by 5 min. Application of
100 μM ostruthin increased TREK currents (100 μM ostruthin). Application of 3 mM bupivacaine blocked the currents nearly completely. (B)
DMSO had no effect, serving as a negative control. (C and D) The current-voltage relationship of the whole-cell TREK-1 currents recorded from
ostruthin- and DMSO-treated cells. The whole cell currents were increased from 0 to 3 min and stayed the same at 5 min. The current was
increased by the addition of ostruthin and that was completely inhibited by bupivacaine. Contrastingly, DMSO had no effect on the current. (E)
The concentration-response curve of ostruthin. The EC50 was found to be 5.3 μM. (n = 5).
https://doi.org/10.1371/journal.pone.0201092.g001
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KCNQ-1 and -3 or HERG-3 channels at 100 μM (data not shown). These results suggested a
weak and general inhibitory effect on K+ channels.
Anxiolytic and antidepressive effects of ostruthin
Reportedly, mice lacking the TREK-2 gene showed a gender-dependent change in anxiety-like
behavior [24]. In addition, riluzole is generally considered as a blocker for Na+ channels and
glutamate receptors, but it can activate TREK-1 channels [9]. Riluzole was also shown to have
anxiolytic and antidepressive effects in humans [8, 25]. Therefore, we tested the effect of
ostruthin on mice anxiety-like behavior in open-field, elevated plus maze, and light/dark
box tests. We administered 0, 2, 5 and 20 mg/kg of ostruthin 30 min before tests. In the open-
field test, one-way ANOVA analysis revealed that the number of entries to the central area was
significantly different depending on doses of ostruthin (F(3, 44) = 21.3, p< 0.00001, n = 12,
Fig 4A). The entries were significantly increased by administration of lower doses of ostruthin
(2 and 5 mg/kg, p< 0.01 and 0.0001, vs 0 mg/kg, post hoc Bonferroni test, n = 12). Total line
crossings were also changed similarly depending on doses (F(3, 44) = 12.6, p< 0.00001, Fig
4B), and were increased by the lower doses (2 and 5 mg/kg, p< 0.0001, vs 0 mg/kg, n = 12). If
ostruthin (5 mg/kg) was equally distributed throughout the mouse body, the concentration
was estimated to be 17 μM, which was higher than the EC50 for TREK-1 but much lower than
the IC50s for other K
+ channels. Of note, a higher dose (20 mg/kg) of ostruthin decreased the
anxiolytic effect, namely the central area entries were significantly decreased (p< 0.0001, vs 5
mg/kg), resulting in a bell-shaped dose-response relationship. A similar decrease in total line
crossings was observed with the higher dose (p< 0.0001, vs 5 mg/kg).
Fig 2. Activation of TREK-2 currents by ostruthin. (A and B) Run-up and activation of TREK-2 channel currents. Whole cell TREK-2
channel currents expressed in 293T cells showed a run-up, which ceased within 3 min. Ostruthin, which was applied 5 min after the
whole-cell access, activated TREK-2 channel currents at 100 μM. The activated current was inhibited by bupivacaine nearly completely.
(C) The concentration-response curve of ostruthin on the TREK-2 currents. The EC50 was found to be 3.7 mM. (n = 5).
https://doi.org/10.1371/journal.pone.0201092.g002
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This anxiolytic effect with the bell-shaped dose-response relationship was also observed in
the elevated plus maze and light/dark box tests. In the elevated plus maze, significant difference
was revealed by one-way ANOVA (F(3, 53) = 18.0, p< 0.00001, n = 12 and 21 (only for 0 mg/
kg), Fig 4C). Lower doses of ostruthin (2 and 5 mg/kg) increased the number of entries to the
Fig 3. Inhibitory effect on other K+ channels. (A) Inhibition of TASK-1 currents. Whole cell TASK-1 currents,
expressed in a 293T cell line, were evoked by step-pulses, as indicated in the protocol. The application of 100 μM
ostruthin inhibited TASK-1 currents in a concentration-dependent manner (n = 10). (B) Inhibition of Kir2.1 currents.
Kir2.1 currents were evoked the step pulses, and application of 100 μM ostruthin decreased the currents by
approximately 60% (n = 5). (C) Inhibition of Kv1.4 currents. Kv1.4 channel currents expressed in a 293T cells were
evoked by depolarizing step pulses with a preceding hyperpolarizing pulse. Ostruthin inhibited the currents (n = 5). (D)
Inhibition of HERG-1 currents. HERG-1 currents were measured as the outward tail current after the depolarizing step
pulses, as shown in the protocol (n = 5).
https://doi.org/10.1371/journal.pone.0201092.g003
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Fig 4. Anxiolytic effect of ostruthin. (A and B) Effect of ostruthin on the anxiety-like behavior of mice was examined
using the open field test. Total numbers of entries into the central area (A) and line crossings (B) made in 5 minutes
were recorded. (C and D) Anxiolytic effect in the elevated plus maze. The number of entries into the open arms (C)
and time spent in the open arms (D) in 5 minutes were measured. (E and F) Anxiolytic effect in the light/dark box test.
The number of transitions between the light and dark boxes (E) and time spent in the light box (F) in 5 minutes were
measured. All the experiments were done 30 min after the administration of PBS (0) or the indicated dose of ostruthin.
https://doi.org/10.1371/journal.pone.0201092.g004
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open arm (p< 0.005 and 0.0001, Bonferroni test, vs 0 mg/kg). Higher dose (20 mg/kg)
decreased the entry to the open arm (p< 0.005, vs 5 mg/kg), resulting in a bell-shaped dose-
response relationship (Fig 4C). Similarly, the time spent on the open-arm was changed in the
same way (F(3, 53) = 47.9, p< 0.00001, Fig 4D). The time was decreased with the highest dose
(p< 0.0001, vs 5 mg/kg).
Consistent results were also observed in the light/dark box test (F(3, 28) = 18.6, p<
0.00001, ANOVA, n = 8, Fig 4E), in which ostruthin increased the number of transitions
between the light and dark boxes (p< 0.001, post hoc Bonferroni test). The transition number
was non-significantly decreased with the highest dose. The time spent in the light box was
changed by ostruthin similarly (F(3, 28) = 34.6, p< 0.00001, n = 8). Osturuthin treatment sig-
nificantly increased the time (p< 0.0001, vs 0 mg/kg). Again the time spent in the light
box was decreased with the administration of 20 mg/kg of ostruthin (p< 0.0005, vs 5 mg/kg),
resulting in a bell-shaped dose–response relationship (Fig 4F). These data consistently showed
the anxiolytic effect of ostruthin.
Reportedly, TREK-1-deficient mice showed a depression-resistant phenotype through
the activation of neurons in the DRN [6]. Because ostruthin activates TREK-1 channels, it is
possible that ostruthin has the opposite effect on depression-like behavior. To test this,
ostruthin-treated mice were subjected to forced swim and tail suspension tests. Unexpect-
edly, ostruthin showed an antidepressive effect in both tests. In the forced swim test, the time
spent immobile was decreased by ostruthin (F(3,28) = 20.5, p< 0.00001, n = 8, Fig 5A). The
decrease in immobile time was dose-dependent. Similarly, administration of ostruthin
decreased the time spent immobile in the tail suspension test (p< 0.005, Student’s t-test,
n = 14, Fig 5B). We also tested the antidepressive effect of social defeat stress, and osturuthin
increased the time difference in the interaction area non-significantly (p = 0.440, Student’s t-
test, n = 14, Fig 5C).
These data consistently suggest the antidepressive effect of ostruthin with the decrease in
the immobile time. But it is also possible that these effects are attributable to an increase in
general locomotor activity. To exclude this possibility, mice used for the elevated plus maze
were subjected to voluntary wheel-running test immediately after the elevated plus maze test
(Fig 5D). Ostruthin had no effect at any dose (F(3,24) = 0.514, p = 0.68, n = 7), suggesting the
unlikelihood of this possibility.
To confirm that TREK-1 channels are involved in these anxiolytic and antidepressive
effects, we administrated ostruthin (5 mg/kg) together with amlodipine (10 mg/kg). Amlodi-
pine is generally used as a Ca2+ channel blocker, but it can block TREK-1 channels too [26].
The effect of co-administration was examined using the elevated plus maze and the tail sus-
pension tests. If ostruthin exhibited anxiolytic and antidepressive effects through the activa-
tion of TREK-1 channels, the co-administration of amlodipine should block these effects. If
amlodipine was equally distributed in the whole body, the dose of 10 mg/kg would be equiva-
lent to 18 μM, which is higher than the reported IC50 for TREK-1 channel currents (0.43 μM)
[26]. One-way ANOVA analysis revealed that the number of entries to the open arm was sig-
nificantly different between four groups (F(3,20) = 5.64, p< 0.01, n = 6, Fig 6A). Whereas
administration of ostruthin increased the number of entries to the open arm (p< 0.05, vs
PBS, post hoc Bonferroni test, n = 6), the administration of amlodipine non-significantly
decreased them (p = 0.10, vs PBS). We then co-administrated ostruthin and amlodipine to
mice. As expected, in the presence of amlodipine, ostruthin did not increase the number
of entries to the open arm (p = 0.47, vs amlodipine, Fig 6A). The number of entries to the
open arm was significantly decreased by co-administration of amlodipine (p< 0.01, vs
ostruthin). Similarly, One-way ANOVA analysis revealed that the time spent in the open arm
was significantly different between four groups (F(3,20) = 5.31, p< 0.01, n = 6, Fig 6B). In
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Fig 5. Antidepressive effect of ostruthin. (A) Effect of ostruthin on the depression-like behavior of mice was
examined using the forced-swim test. The amount of time spent immobile in the last 4 min of the swimming period (6
min) was recorded. Administration of ostruthin 30 min before test significantly reduced the time spent immobile in a
dose-dependent manner. (B) Antidepressive effect of ostruthin in the tail-suspension test. The amount of time spent
immobile was recorded for 5 min. (C) Insignificant effect on social defeat stress test. After the exposure to aggressor
ICR mice for 9 days, C57BL/6J test mouse was placed in an open-field arena. Firstly the time spent around the empty
enclosure and subsequently that with an unfamiliar ICR mouse was measured. The former duration was subtracted
from the later. (D) Lack of effect on voluntary motility. After the end of the elevated plus maze, mice were subjected to
voluntary wheel running test for 5 min. All experiments were carried out 30 min after the administration of PBS (0) or
the indicated dose of ostruthin.
https://doi.org/10.1371/journal.pone.0201092.g005
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Fig 6. Effect of co-administration of amlodipine on the anxiolytic and antidepressive effects of ostruthin. (A and
B) Blockade of the anxiolytic effect of ostruthin by co-administration of amlodipine in the elevated plus maze. Mice
were administrated the compounds 30 min before the test. Although administration of ostruthin increased the number
of entries into the open arm (A) and the time spent on the open arm (B), co-administration with amlodipine blocked
the increase. (C) Blockade of the antidepressive effect of ostruthin by co-administration of amlodipine in the tail
suspension test. Although administration of ostruthin decreased the immobile time, it did not do so in the presence of
amlodipine. (D) Pre-administration of amlodipine effectively blocked the antidepressive effect of ostruthin compared
with pre-administration of PBS.
https://doi.org/10.1371/journal.pone.0201092.g006
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the absence of amlodipine, ostruthin increased the time spent in the open arm (p< 0.05, PBS
vs ostruthin, n = 6, Fig 6B), whereas it did not in the presence of amlodipine (p = 0.47). The
co-administration of amlodipine significantly decreased the time spent in the open arm
(p< 0.01, vs ostruthin). These results suggest the involvement of TREK-1 channels in the
anxiolytic effect of ostruthin.
This is the case even for the antidepressive effect examined with the tail suspension test
(Fig 6C). One-way ANOVA analysis revealed that the immobile time was significantly differ-
ent between four groups (F(3,36) = 2.94, p< 0.05, n = 9 and 13 (only for ostruthin)). In the
absence of amlodipine, the time spent immobile was significantly decreased by ostruthin-
treatment (p<0.01, post hoc Bonferroni test, PBS vs ostruthin, n = 9 and 13). That of amlodi-
pine-treated mice was non-significantly decreased (p = 0.10, vs PBS, n = 9). In the presence
of amlodipine, ostruthin had no effect on the time spent immobile (p = 0.53), suggesting the
involvement of TREK-1 channels in the antidepressive effect too. The co-administration of
amlodipine with ostruthin increased the immobile time compared with ostruthin, but the dif-
ference was not significant (p = 0.17). This might be attributable to an insufficient blockade
with co-administration of amlodipine. To test this, we administrated PBS or amlodipine 30
min before ostruthin administration and examined the antidepressive effect 30 min after the
ostruthin injection (Fig 6D). One-way ANOVA analysis revealed that the immobile time was
significantly different between three groups (F(2,21) = 5.42, p< 0.05, n = 8). As expected,
preceding administration of amlodipine significantly increased the immobile time compared
with preceding PBS administration (p< 0.05, PBS!ostruthin vs amlodipine!ostruthin,
n = 8), suggesting the efficient blockade with preceding administration of amlodipine. After
the pre-administration of amlodipine, the secondary ostruthin administration was ineffec-
tive, namely the immobile time was similar to that of the secondary PBS-administration
(p = 0.22).
Effect of ostruthin on anti-c-Fos immunoreactivity of stressed-mouse
brains
The above findings raised a question about which nucleus is involved in these behavioral
effects, on the assumption that ostruthin changed the neuronal activity of a nucleus and
thereby changed the behavior of the mice. Is it the same as current drugs? To determine the
nucleus involved, through which ostruthin exhibited its anxiolytic and antidepressive effects,
we examined the effect of ostruthin on anti-c-Fos immunoreactivity, which is a marker of neu-
ronal activity [27], in anxiety and depression related nuclei. We first examined the immunore-
activity in non-stressed animals, which only received PBS or ostruthin administration and
were fixed 30 min after. Modest anti-c-Fos immunoreactivities were observed in some nuclei,
but there was no difference between PBS- and ostruthin-treated mice (data not shown), sug-
gesting that ostruthin had little effect on basal neuronal activity.
We then examined anti-c-Fos immunoreactivity 30 min after mild stress, i.e., being sub-
jected to the tail suspension test. The mild-stress of the tail suspension test significantly
increased anti-c-Fos immunoreactivity in stress-related nuclei, i.e. the lateral septum (LS,
F(2,9) = 10.6, p< 0.005, n = 4, Fig 7A), hypothalamic paraventricular nucleus (PVN, F(2,9) =
12.7, p< 0.005, Fig 7B), thalamic paraventricular nucleus (PVT, F(2,9) = 4.38, p< 0.05, Fig
7C), central amygdala (CeA, F(2,9) = 19.9, p< 0.001) and basolateral amygdala (BLA, F(2,9) =
19.5, p< 0.001, Fig 7D), and dorsal (DRD, F(2,9) = 5.88, p< 0.05) and ventral nuclei of the
dorsal raphe (DRV, F(2,9) = 10.1, p< 0.005, Fig 7E). We counted the number of immunoreac-
tive neurons in these nuclei and found that these were significantly increased in response to
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the stress. We then examined the effect of ostruthin (5 mg/kg) on the stressed mice and found
that there were no significant differences in most nuclei (Fig 7B–7E). However, only in the
LS, ostruthin significantly suppressed the stress-induced increase in c-Fos immunoreactivity
(Fig 7A).
Fig 7. Stress-induced increase in anti-c-Fos immunoreactivity and suppression by ostruthin in the LS. (A) Anti-c-Fos
immunoreactivity in the LS of non-treated and stressed mice. Anti-c-Fos-immunoreactivity was increased by stress-
treatment, and the increase was suppressed by ostruthin. (B-E) The numbers of anti-c-Fos-immunoreactive cells were also
increased by stress-treatment in the hypothalamic paraventricular nucleus (B), thalamic paraventricular nucleus (C), central
and basolateral amygdala (D), and dorsal and ventral dorsal raphe nuclei (E). Ostruthin did not suppress the increase in these
nuclei. LV indicates the position of the lateral ventricle; 3V, third ventricle; Aq, central aqueduct; CeA, central amygdala;
BLA, basolateral amygdala; DRD, dorsal raphe nuclei; DRV, ventral raphe nuclei. (ANOVA followed by Bonferroni test; ,
p<0.05; , p< 0.01; , p<0.005; n = 4; Bar, 100 μm).
https://doi.org/10.1371/journal.pone.0201092.g007
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Discussion
Effect of ostruthin on K+ channels
Previous reports showed that ostruthin has several biological activities, such as mitochon-
drial uncoupling [28], antimycobacterial activity [29], inhibition of smooth muscle cell pro-
liferation [30], and inhibition of cell differentiation [31]. Here, we demonstrated that a
botanical compound, ostruthin, activated TREK-1 channels at a low concentration, and
TREK-2 channels at a higher concentration. Because K+ ions are essential for plant cell
growth, osmoregulation, and stomatal opening, K+ ions absorbed from the soil are trans-
ported to the stems and leaves. For this reason, plant cells express many kinds of K+ chan-
nels, including TREK-like channels, which are expressed in the plasma membrane and
tonoplast [12]. Therefore, compounds that activate TREK channels might be useful for plants
as natural enhancers of K+ ion transport. Our present results indicated that botanical com-
pounds are a promising resource for the identification of new lead compounds that can act
as K+ channel modifiers.
TREK-1 channels were activated by arachidonic acid, docosahexaenoic acid, riluzole, and
inhalational anesthesia [22, 32]. Inhalational anesthesia, i.e., halothane, isoflurane, diethyl
ether, and Chloroform, was shown to bind to the intracellular C-terminal domain [33].
Ostruthin has features of the cell membrane- and blood-brain barrier-permeability: 1) low
molecular weight (298), 2) small number of hydrogen bond donor (2) and acceptors (2), 3)
modestly high partition coefficient (5.6), 4) small polar surface area (50.4 Å2). These features
closely matched Lipinski’s rule of five. Therefore, ostruthin might bind to the intracellular C-
terminal domain and activate the channel. On the other hand, ostruthin inhibited most other
K+ channels at higher concentrations. Ostruthin might bind to a site, of which amino acid
sequences are similar among these ostruthin-sensitive K+ channels, i.e. K+ ion filter and pore
domain.
Anxiolytic and antidepressive effects of ostruthin
Ostruthin consistently showed an anxiolytic effect in open-field, elevated plus maze, and light/
dark box tests at a low dose (5 mg/kg). The involvement of TREK-1 channels in this anxiolytic
activity was suggested by the inhibition of the effect of ostruthin by the co-administration of
amlodipine, a blocker of TREK-1 channels. It was reported that riluzole, an activator for
TREK-1 channels [9], showed anxiolytic effects [34], although riluzole has various pharmaco-
logical activities, e.g. blockade of NMDA receptors and voltage-dependent Na+ channels and
inhibition of G-protein-dependent signal transduction [8]. Activation of TREK-1 channels
might be the common mechanism for the anxiolytic activity of riluzole and ostruthin at least
in part. Of note, an increased dosage of ostruthin (20 mg/kg) reduced the effect and resulted in
a bell-shaped dose-response relationship. This might be attributable to ostruthin activating
TREK channels at low concentration but inhibiting other K+ channels at higher concentra-
tions. Namely, low-dose ostruthin suppressed anxiety-related neurons by activation of TREK-
1 channels, whereas high-dose ostruthin activated neuronal activity by the inhibition of other
K+ channels.
Ostruthin also showed an antidepressive effect in forced swim and tail suspension tests. The
involvement of TREK-1 channels was again confirmed by blockade of the behavioral effect by
co-administration of amlodipine. A previous study showed the antidepressant properties of
riluzole in patients with treatment-resistant depression [25], although the authors paid atten-
tion to the anti-glutamatergic effect of riluzole rather than the effect on TREK-1 channels. In
addition, openers for another K+ channel, KCNQ, were shown to have an antidepressive effect
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[35]. Thus, the activation of K+ channels might be the mechanism for the antidepressive effects
of these compounds.
The immobile times were decreased in the forced swim and tail-suspension tests, and motil-
ity was increased in the open-field test. Therefore, it is possible that these antidepressant-like
behaviors may be attributable to the increase in general motility. Although we could not
exclude this possibility, other data suggest the low likelihood of this possibility: 1) Lack of effect
of ostruthin on wheel running, which reflect voluntary general motility. 2) An insignificant
increase in the time spent in the target zone in social defeat stress test.
Possible differences in the mechanism of action from current drugs
Current antidepressants inhibit the reuptake of serotonin and norepinephrine and thereby
enhance their transmission. Previous studies reported the involvement of TREK-1 channels in
depression-like behavior in mice through the activation of neurons in the DRN [6, 10, 36]; it
was explained that inhibition of TREK-1 channels led to the activation of serotonergic neurons
in the nucleus and the enhancement of serotonin release. Indeed, Heuteaux et al. observed
increases in spontaneous firing rates in TREK-1-deficient mice [6]. A serotonin-specific reup-
take inhibitor, fluoxetine, inhibited TREK-1 channels in the μM range; therefore, its behavioral
effect was considered to be attributable to the inhibition of the channels in the DRN neurons
in part [37]. In contrast, we found that an activator of TREK-1, ostruthin, showed an antide-
pressive effect. In addition, our anti-c-Fos immunostaining examination failed to detect
ostruthin-dependent changes in neuronal activities of the DRN. Instead, ostruthin significantly
suppressed the stress-induced increase in c-Fos immunoreactive cells only in the LS. Ostruthin
might exhibit its antidepressive effect through this nucleus rather than the DRN.
The possible mechanism for the anxiolytic activity of ostruthin also seemed to be different
from current anxiolytic drugs. A commonly used anxiolytic group of medicines, benzodiaze-
pines, enhance inhibitory GABAergic transmission and thereby inhibit anxiety-related neu-
rons in the limbic system including the amygdala [38]. However, ostruthin had no effect on
the stress-induced increase in anti-c-Fos immunoreactivity in the amygdala, on which current
anxiolytic agents act. Indeed, our preliminary data showed that ostruthin had no effect on the
amplitude or frequency of GABAergic mIPSCS in the amygdala neurons at 100 μM. Instead,
ostruthin suppressed stress-induced activation of the LS. Thus, ostruthin may exhibit anxio-
lytic effects via a different neural pathway from benzodiazepines.
The LS is known to be involved in the anxiety- and depression-like behaviors [39]. Further-
more, the LS was reported to be involved in freezing behavior and relay the information of
stress to other nuclei [27]. The suggested role of the LS neurons in the anxiety-like behavior
was controversial: some reports suggested that the LS suppresses anxiety behavior [39, 40],
whereas others suggested that the nucleus promotes anxious behaviors [41]. In either case, it is
commonly assumed that the LS relays the information of stress to other nuclei. Thus, the sup-
pression of the LS by ostruthin would be an indication of suppression of the relay. Mental
stress can lead to both anxiety and depression, and therefore it is expected that ostruthin is
effective in humans, especially for the drug-resistant cases.
It remains unclear how ostruthin suppressed the increase in anti-c-Fos immunoreactivity
in the LS without affecting the other nuclei. It is likely that ostruthin directly activated TREK-1
channels expressed in the LS and thereby suppressed the stress-induced increase in neuronal
activity. Indeed, a modest expression of TREK-1 mRNA was shown in the LS [5]. Another pos-
sibility is that ostruthin might indirectly affect neuronal activity in another nucleus and
thereby inhibit activity in the LS. Finally, ostruthin might exert these inhibitory effects through
the blockade of other K+ channels. The last possibility is, however, unlikely because the IC50s
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for other K+ channels were in the hundreds of μM range, which were higher than the estimated
concentration caused by the dosage of 5 mg/kg. Furthermore, the involvement of TREK-1
channels was indicated by the blockade of the anxiolytic and antidepressive effects by the co-
administration of amlodipine. Further work is needed to clarify this mechanism.
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